October 10, 2011
Ono Pharmaceutical announced on September 29 that Onyx Pharmaceuticals, Inc. completed an NDA submission to the US FDA under the accelerated approval process for carfilzomib, a next-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma (MM), on...read more